Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over

BACKGROUND: In the Republic of Korea (Korea), the NVX-CoV2373 (Novavax) coronavirus disease 2019 (COVID-19) vaccination was administered to 18-year-olds and over from February 14, 2022. This study sought to assess the frequency and severity of reported adverse events following the Novavax COVID-19 v...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seontae, Ko, Mijeong, Heo, Yesul, Lee, Yeon-Kyeng, Kwon, Yunhyung, Choi, Seok-Kyoung, Bahng, Eunok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293897/
https://www.ncbi.nlm.nih.gov/pubmed/37422379
http://dx.doi.org/10.1016/j.vaccine.2023.06.077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293897/
https://www.ncbi.nlm.nih.gov/pubmed/37422379
http://dx.doi.org/10.1016/j.vaccine.2023.06.077

Ejemplares similares